Genmab A/S ADS GMAB
Analyst Ratings
- Consensus
- Buy — 7 Buy · 1 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $42.94 (-1.9% downside)
Key Stats
- Today's Range
- $39.63 – $44.34
- 50-Day Range
- $31.14 – $44.34
- 52-Week Range
- $23.62 – $44.34
- Volume
- 13.00 million shs
- Average Volume
- 4.14 million shs
- Market Cap
- $26.93 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Related Stocks
Compare head-to-head: GMAB vs NVDA·GMAB vs AAPL·GMAB vs GOOGL·GMAB vs MSFT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.